AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Phase IIa Study Assessing the Effects of AZD1236 on Biomarkers in Chronic Obstructive Pulmonary Disease (COPD) Patients
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2015-04-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 55
- Registration Number
- NCT00758706
- Locations
- 🇳🇴
Research Site, Trondheim, Norway
Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin
Phase 3
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: Saxagliptin, 5 mg + insulinDrug: Placebo + insulin
- First Posted Date
- 2008-09-23
- Last Posted Date
- 2015-06-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 455
- Registration Number
- NCT00757588
- Locations
- 🇺🇸
Clinical Research Advantage, Inc, Tempe, Arizona, United States
🇺🇸Southgate Medical Group, West Seneca, New York, United States
🇺🇸Valley Research, Fresno, California, United States
AZD3355 Dose-escalation Study in Healthy Males
- First Posted Date
- 2008-09-23
- Last Posted Date
- 2010-12-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 54
- Registration Number
- NCT00757419
- Locations
- 🇸🇪
Research Site, Gothenburg, Sweden
A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Cystic Fibrosis
- First Posted Date
- 2008-09-23
- Last Posted Date
- 2012-08-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 56
- Registration Number
- NCT00757848
- Locations
- 🇬🇧
Research Site, Liverpool, United Kingdom
Treatment Clinical Practice in Bipolar Depression in Spain
Completed
- Conditions
- Bipolar Depression
- First Posted Date
- 2008-09-23
- Last Posted Date
- 2009-02-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 378
- Registration Number
- NCT00757328
- Locations
- 🇪🇸
Research Site, Valladolid, Spain
AZD8529 Single Ascending Dose Study
- First Posted Date
- 2008-09-19
- Last Posted Date
- 2009-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 58
- Registration Number
- NCT00755378
- Locations
- 🇺🇸
Research Site, Philadelphia, Pennsylvania, United States
Study to Assess Safety, Tolerability and Pharmacokinetics After Single Doses of AZD2516 to Healthy Volunteers
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2008-12-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 72
- Registration Number
- NCT00754715
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin
- First Posted Date
- 2008-09-17
- Last Posted Date
- 2015-04-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 134
- Registration Number
- NCT00753896
- Locations
- 🇿🇦
Research Site, Pretoria, South Africa
Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer
- First Posted Date
- 2008-09-16
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 265
- Registration Number
- NCT00753545
- Locations
- 🇬🇧
Research Site, Wirral, United Kingdom
To Evaluate the Effect of Food on the Pharmacokinetics (PK) of AZD0328
- First Posted Date
- 2008-09-15
- Last Posted Date
- 2008-10-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT00752830
- Locations
- 🇸🇪
Research Site, Lund, Sweden
© Copyright 2025. All Rights Reserved by MedPath